Gregg Williams, a director and 10% owner of Vivani Medical, Inc. (NASDAQ: VANI), has executed a significant insider purchase, acquiring 793,650 shares of the company's common stock for a total consideration of $999,999. The transaction was finalized on July 15, 2026, with each share acquired at a price point of $1.26. This acquisition was structured as a private sale, governed by a Share Purchase Agreement dated August 11, 2025. The agreed price of $1.26 per share corresponded with the last reported sale price of Vivani Medical's common stock on the Nasdaq exchange on August 10, 2025, which was the day immediately preceding the agreement date.
Following this transaction, Mr. Williams' total direct and indirect holdings in Vivani Medical have increased to 41,711,936 shares. This aggregate position includes 4,799,200 shares held directly by Mr. Williams. The remaining shares are distributed across various entities over which Mr. Williams retains voting and dispositive power. These entities include the Gregg G. Williams 2006 Trust, which holds 34,786,984 shares; Williams International Co. LLC, holding 1,212,856 shares; Sam Williams Family Investments LLC, with 181,587 shares; and the Sam B. Williams 1995 Generation-Skipping Trust, which holds 731,309 shares. The current market price of the stock stands at $1.41, representing an increase from the $1.26 purchase price, although the stock has experienced a decline of approximately 10% over the past week. Financial analysis suggests the stock may be overvalued relative to its Fair Value estimate, despite analysts maintaining price targets between $3.50 and $4.00.
In parallel developments, Vivani Medical has announced an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide drug implant designed for chronic weight management. This agreement does not include exclusivity provisions for NPM-139 or Vivani's NanoPortal platform technology. Additionally, Vivani Medical received approval from Bellberry in Australia to commence the SLIM-1 Phase 1 clinical trial of the semaglutide implant in mid-2026. The trial will compare a low-dose NPM-139 with Wegovy in obese or overweight subjects. In a significant corporate restructuring, Vivani Medical entered into a merger agreement involving its subsidiary Cortigent Inc and ClearOne Inc. As a result, Vivani will acquire 12,500,000 shares of ClearOne common stock. In terms of leadership changes, Vivani Medical appointed August Moretti to its board of directors, succeeding Dr. Dean Baker, who retired. Mr. Moretti will chair the Audit Committee and serve on the Compensation Committee.
On the analyst front, H.C. Wainwright reiterated a Buy rating on Vivani Medical with a price target of $3.50 following the Novo Nordisk agreement. Furthermore, Lake Street initiated coverage on Vivani Medical with a Buy rating and a price target of $4.00, emphasizing the company's implant technology for long-term medication delivery. These developments reflect Vivani Medical's strategic moves and ongoing advancements in its medical technology initiatives.